JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors
Clinical trial NCT02904226 · COMPLETED
Trial details
- NCT number
- NCT02904226
- Sponsor
- Jounce Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-08-01
- Primary completion
- 2020-07-01
- Enrollment
- 242
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.